SCHEMBL3989419

SCHEMBL3989419

COc1cccc(-c2ccc3c(c2)CCC3=O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.55
CYP11B2 P19099 2/20 0.55
CYP1A2 P05177 1/20 0.55
HSD17B1 P14061 4/20 0.54
CHEK1 O14757 1/20 0.50
ALKBH3 Q96Q83 1/20 0.49
BRD4 O60885 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HSD17B3 P37058 1/20 0.48
MAPK1 P28482 1/20 0.47
MAPKAPK2 P49137 1/20 0.47
ADORA1 P30542 1/20 0.46
CD274 Q9NZQ7 1/20 0.46
DHODH Q02127 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
DRD4 P21917 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4085727 0.91 HSD17B1 (0.60) CYP11B1CYP11B2CYP1A2HSD17B1CHEK1
SCHEMBL1745460 0.86 HSD17B1 (0.63) CYP11B1CYP11B2CYP1A2HSD17B1HSD17B3
SCHEMBL268592 0.82 KDM4E (0.56) CYP1A2
SCHEMBL6968452 0.81 HRH3 (0.57) CYP11B1CYP11B2CYP1A2HSD17B1DHODH
SCHEMBL3992710 0.81 CYP1A1 (0.55) CYP1A2HSD17B1MAPK1ADORA1
Water SCHEMBL28454486 0.80 KDM4E (0.54) CYP1A2MAPK1
SCHEMBL8154135 0.80 PARP10 (0.69) CHEK1MAPKAPK2CD274
SCHEMBL28655414 0.80 HSD17B1 (0.78) CYP11B1CYP11B2CYP1A2HSD17B1
SCHEMBL13680642 0.80 PARP10 (0.64) CYP11B1CYP11B2CYP1A2HSD17B1DHODH
SCHEMBL1745161 0.79 HSD17B1 (0.71) CYP11B1CYP11B2CYP1A2HSD17B1HSD17B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7485655-B2 2-Aminothiazole allosteric enhancers of A1 adenosine receptors UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2009-02-03 US disclosed
EP-1583530-A4 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1-ADENOSINE RECEPTORS UNIV VIRGINIA (US) 2008-07-23 EP disclosed
EP-1583530-A1 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1-ADENOSINE RECEPTORS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2005-10-12 EP disclosed
US-20050027125-A1 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-02-03 US disclosed
WO-2003061655-A1 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1 ADENOSINE RECEPTORS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050027125-A1 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors ADORA1, ADORA2A, ADORA2B CYP11B1 1981/4885CYP11B2 2721/4885CYP1A2 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.